underscored as the region has recorded some of the highest rates (1), reporting 80% of the cervical cancers in the world (2). With a population of over 1 million women ages 15 years and older at risk of developing HPV (3) , Jamaica boasts a world leading prevalence rate of 54% (4), 35 % of which is oncogenic (5), the highest incidence being among the younger age groups.
HPV is also responsible for oral, vuval, vaginal and anal cancers in women and penile oral and anal cancers in men. The recommendation for the immunization of adolescent girls with the HPV vaccine before exposure to the virus will result in reduced incidence of cervical cancer (1) and other HPV causing cancers. It is agreed that the benefits of the HPV vaccine are significant though the cost is prohibitive and the average Jamaican who is most likely at the highest risk may not be able to afford this life saving drug. For developing countries like Jamaica, the affordability also depends on the proposed cohort to be vaccinated. With no HPV programme in place, the Government of Jamaica should make every effort to introduce this vaccine in the Expanded Programme of Immunization (EPI) in Jamaica. This will be a welcomed addition to the current fight against vaccine preventable diseases. However, the inclusion of boys into the cohort will have to be taken after its' introduction to girls and after much consultation. Studies have identifies the benefits of herd immunity if a minimum of 50% of females are vaccinated (6) . With Jamaica's history of exceptional vaccine coverage of over 90% for most vaccines a 50% coverage in HPV is achievable. In the interim, improved screening programmes will aid in the identification of pockets of vulnerability and classification of target groups. Additionally, the introduction of the vaccine to all females will eventually result in herd immunity that will essentially provide protection for our boys and men. 
